Breaking News, Collaborations & Alliances

Bio-Thera, STADA Extend Biosimilars Alliance to Tocilizumab

Tocilizumab is a targeted immunomodulatory monoclonal antibody directed against the interleukin-6 receptor, indicated to treat multiple inflammatory and autoimmune disorders.

By: Rachel Klemovitch

Assistant Editor

Bio-Thera Solutions, a commercial-stage biopharmaceutical company, and STADA Arzneimittel AG, a consumer healthcare medicines company, have agreed to extend their biosimilars alliance to cover tocilizumab. Tocilizumab is an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement covering tocilizumab is subject to shareholder approval. This agreement for tocilizumab builds upon an existing partnership on similar terms for BAT25...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters